« Back
Home /
SARS-CoV-2 Spike RBD Antibody [2381]

SARS-CoV-2 Spike RBD Antibody [2381]

Item no.	PRS-10-059-0.1mg
Manufacturer	ProSci
Amount	0.1 mg
Category	Infectious Diseases Viral Infections Coronavirus (COVID-19) Antibodies ELISA Primary Antibodies
Type	Antibody Primary
Format	Liquid
Applications	ELISA
Clone	2381
Specific against	other
Isotype	IgG1
Conjugate/Tag	Unconjugated
Citations	Huo J, Zhao Y, Ren J, et al. Cell Host Microbe. S1931-3128(20)30351-6. 2020 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), is an enveloped, single-stranded, positive-sense RNA virus that belongs to the Coronaviridae family 1. The SARS-CoV-2 genome, which shares 79.6% identity with SARS-CoV, encodes four essential structural proteins: the spike (S), envelope (E), membrane (M), and nucleocapsid protein (N) 2. The S protein is a transmembrane, homotrimeric, class I fusion glycoprotein that mediates viral attachment, fusion, and entry into host cells 3. Each ~180 kDa monomer contains two functional subunits, S1 (~700 a.a) and S2 (~600 a.a), that mediate viral attachment and membrane fusion, respectively. S1 contains two major domains, the N-terminal (NTD) and C-terminal domains (CTD). The CTD contains the receptor-binding domain (RBD), which binds to the angiotensin-converting enzyme 2 (ACE2) receptor on host cells 3-5. Although both SARS-CoV and SARS-CoV-2 bind the ACE2 receptor, the RBDs only share ~73% amino acid identity, and the SARS-CoV-2 RBD binds with a higher affinity compared to SARS-CoV 3, 6. The RBD is dynamic and undergoes hinge-like conformational changes, referred to as the “down” or “up” conformations, which hide or expose the receptor-binding motifs, respectively 7. Following receptor binding, S1 destabilizes, and TMPRSS2 cleaves S2, which undergoes a pre- to post-fusion conformation transition, allowing for membrane fusion 8, 9. Polyclonal RBD-specific antibodies can block ACE2 binding 10, 11, and anti-RBD neutralizing antibodies are present in the sera of convalescent COVID19 patients 12, identifying the RBD as an attractive candidate for vaccines and therapeutics. In addition, the RBD is poorly conserved, making it a promising antigen for diagnostic tests 13 14. Serologic tests for the RBD are highly sensitive and specific for detecting SARS-CoV-2 antibodies in COVID19 patients 13 15. Furthermore, the levels of anti-RBD antibodies correlated with SARS-CoV-2 neutralizing antibodies, suggesting the RBD could be used to predict an individual's risk of disease 13. Zhou, P., Yang, X., Wang, X. et al. Nature 579, 270–273. 2020. Wu, F., Zhao, S., Yu, B. et al. Nature 579, 265–269. 2020. Wrapp D, Wang N, Corbett KS, et al. bioRxiv. 2020.02.11.944462. 2020. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Cell. 181(2):281-292.e6. 2020. Li W, Zhang C, Sui J, et al. EMBO J. 24(8):1634-1643. 2005. Shang, J., Ye, G., Shi, K. et al. Nature 581, 221–224. 2020. Gui M, Song W, Zhou H, et al. Cell Res. 27(1):119-129. 2017. Walls AC, Tortorici MA, Snijder J, et al. Proc Natl Acad Sci U S A. 114(42):11157-11162. 2017. Hoffmann M, Kleine-Weber H, Schroeder S, et al. Cell. 181(2):271-280.e8. 2020.
ECLASS 10.1	32160702
ECLASS 11.0	32160702
UNSPSC	12352203
Alias	SARS-CoV-2 Spike RBD Antibody, Receptor Binding Domain Antibody
Available
Manufacturer - Applications	ELISA (Quality Tested by ProSci)
Manufacturer - Isotype	Human IgG1
Shipping Temperature	blue ice or room temperature
Storage Conditions	Functional grade preclinical antibodies may be stored sterile as received at 2-8° C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80° C. Avoid Repeated Freeze Thaw Cycles.
Manufacturer - Research Area	Infectious Disease, COVID-19
Protein Gi #	SARS-CoV-2
Purification	>95% by SDS Page
Concentration	>1.0 mg/ml
Buffer	This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (PBS) pH 7.2 - 7.4, 150 mM NaCl with no carrier protein, potassium, calcium or preservatives added.
Immunogen	Sequenced from human survivors of COVID-19 (SARS-CoV-2). The spike RBD is expressed on the surface of SARS-CoV-2.
Clonality	Monoclonal
Disclaimer	Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 0.1 mg

available

Delivery expected until 9/4/2025

Express Delivery: Save 22 days

Compare

Add to wishlist

Get an offer